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Summary
Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related death worldwide, 
with an overall 5-year survival rate of only 10–15% 1. Deregulation of the Ras pathway is a 
frequent hallmark of NSCLC, often through mutations that directly activate Kras 2. p53 is also 
frequently inactivated in NSCLC and, since oncogenic Ras can be a potent trigger of p53 3, it 
seems likely that oncogenic Ras signalling plays a major and persistent part in driving the 
selection against p53. Hence, pharmacological restoration of p53 is an appealing therapeutic 
strategy for treating this disease 4. Here, we model the likely therapeutic impact of p53 restoration 
in a spontaneously evolving mouse model of NSCLC initiated by sporadic oncogenic activation of 
endogenous Kras 5. Surprisingly, p53 restoration failed to induce significant regression of 
established tumours although it did result in a significant decrease in the relative proportion of 
tumours classed as high grade. This is due to selective activation of p53 only in the more 
aggressive tumour cells within each tumour. Such selective activation of p53 correlates with 
marked up regulation in Ras signal intensity and induction of the oncogenic signalling sensor 
p19ARF 6. Our data indicate that p53-mediated tumour suppression is triggered only when 
oncogenic Ras signal flux exceeds a critical threshold. Importantly, the failure of low-level 
oncogenic Kras to engage p53 reveals inherent limits in the capacity of p53 to restrain early 
tumour evolution and to the efficacy of therapeutic p53 restoration to eradicate cancers.
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Inactivation of the p53 tumour suppressor pathway is a common feature of human cancers, 
fostering the attractive notion of restoring p53 function in established tumours as an 
effective and tumour-specific therapeutic strategy 4. Indeed, p53 restoration was recently 
shown to trigger dramatic tumour regression in vivo 7–9. While encouraging, these studies 
utilized tumour models (either transgene 7,9 or radiation-induced 8) driven by 
preternaturally high levels of oncogenes. Because high-level oncogene activity potently 
engages p53 via the p19ARF tumour suppressor 6,7,10, p53 restoration has a dramatic impact 
in these models. Unlike high oncogenic activity, however, low-level expression of dominant 
oncogenes appears insufficient to engage intrinsic tumour suppression, even though it still 
suffices to drive tumourigenesis 11,12. This raises the spectre that many epithelial 
malignancies, initiated as they are by low-level oncogenic signals such as those arising from 
mutational activation of ras genes in situ, may be insensitive to p53 restoration - at least 
during certain phases of their evolution. To investigate this possibility we assessed the 
ability of p53 restoration to trigger tumour regression in the well-characterized Lox-Stop-
Lox-KrasG12D (KR) murine tumour model of NSCLC 5 wherein tumourigenesis is driven by 
sporadic, low-level activation of mutant Kras. This model closely recapitulates its human 
disease counterpart 13.
After inhalation of adenovirus-Cre, KR mice develop multiple, independently evolving lung 
tumours, permitting contemporaneous analysis of different disease stages within each 
animal. KR mice were crossed into the p53KI/KI switchable mouse model in which both 
alleles of the endogenous p53 gene are replaced by the conditional variant p53ERTAM 14. 
p53KI/KI mice can be reversibly toggled in vivo between p53 wild-type (wt) and p53 null 
states by administration or withdrawal of Tamoxifen (Tam). Importantly, once functionally 
restored in Tam-treated p53KI/KI mice, p53-mediated tumour suppression is triggered only if 
p53-activating signals are present 7,10.
KrasG12D was sporadically activated in KR;p53KI/+ and KR;p53KI/KI lungs and tumours 
allowed to develop for 16 weeks. In both genotypes, KrasG12D activation induced a 
spectrum of lung tumour grades including hyperplasias, adenomas and adenocarcinomas. 
Like KR;p53-deficient animals 15 (Supplementary Figure 1), KR;p53KI/KI mice exhibit 
accelerated tumour progression and increased incidence of high-grade tumours relative to 
their KR;p53KI/+ counterparts. These data affirm that p53 restrains Kras-driven NSCLC yet 
indicate that, even when combined, KrasG12D activation and p53 inactivation are insufficient 
to generate malignant tumours without additional, aleatory mutations.
To ascertain its therapeutic impact, p53 function was restored for one week in KR;p53KI/KI 
lung tumours (Figure 1A). Surprisingly, given the dramatic tumour regression induced by 
p53 restoration in other models 7–9, p53 restoration had no macroscopically evident impact 
on these tumours (Figure 1B). Close inspection, however, indicated that p53 restoration did 
elicit a modest decrease in proliferating tumour cells (Figure 1C; 13.99% Ki67 positive cells 
per Tam-treated tumours versus 20.97% in controls) and an increase in apoptosis 
(Supplemental Figure 2 and Figure 1D; 45% of p53-restored tumours contain apoptotic cells 
versus 13.5% of control tumours). Nevertheless, the distribution of apoptotic cells in 
tumours following p53 restoration was irregular and clustered (Figure 1E). This high 
variability in the response to sustained p53 restoration was confirmed by microCT imaging 
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of individual tumours over 7 days. While all control tumours grew during treatment, 
individual Tam-treated tumours exhibited all possible responses – some grew, others were 
unchanged, and many shrank (Figure 2A and Supplemental Figure 3). Such variability in 
tumour response to Tam might reflect heterogeneities among tumor cells in the efficiency of 
p53 restoration, in the presence of p53-activating signals, or in the engagement of 
downstream effectors following p53 restoration. To determine which, we first ascertained 
the efficiency with which Tam restored p53 function in tumours. Mice were treated for 7 
days with Tam or vehicle and then exposed to a single dose of γ-radiation (IR) 2 hrs after the 
last treatment to activate p53 directly. p53 activity was then monitored in individual tumours 
by assaying induction of the prototypical p53-responsive gene, CDKN1A (p21cip1) 16,17. 
All tumours showed substantial CDKN1A induction (Figure 2B), indicating that systemic 
Tam pervasively restores p53 function in all tumours. Hence, the heterogeneity of the 
therapeutic response to Tam is not a consequence of either variability in Tam-dependent p53 
restoration or in the capacity of p53, once activated, to induce CDKN1A. By contrast, when 
p53 function was restored in the absence of concomitant DNA damage, CDKN1A was 
induced in only a minority of tumours (Figure 2B). Hence, the variability in response to p53 
restoration is because only a minority of tumours harbour endogenous p53-activating 
signals. Interestingly, whereas we see abundant apoptosis in aggressive tumour cells 
following p53 restoration, Feldser et al. in an accompanying paper do not 18, even though 
their mouse lung tumour model driven by spontaneous, sporadic KRas activation is 
ostensibly similar to ours. The reasons for this are unclear. However, the models differ in 
several ways. First, the mechanism of KRas activation is different, and may target distinct 
cell lineages with innately different sensitivities to p53-induced apoptosis. Second, they use 
Cre-lox recombination to restore p53 function, which is innately less synchronous than in 
our p53ERTAM model and may make it difficult to see a transient wave of cell death. Cre-
lox recombination may also introduce additional genotoxic stresses that further modify p53 
output. In the end, however, whether apoptosis or senescence is the principal output of p53 
restoration in aggressive tumour cells may not be so important since that both p53-induced 
apoptosis 7 and senescence 9 are effective at eliciting tumour clearance.
Although p53 may be activated by a wide-range of stress signals, recent in vivo studies 
implicate induction of p19ARF by oncogenic signalling as the critical p53-activating trigger 
in established tumours 7,10. Since oncogenic Ras can be a potent inducer of p19ARF 19, we 
assayed for p19ARF expression in KR;p53KI/KI lung tumours. Immunohistochemical analysis 
(IHC) of KR;p53KI/KI lungs revealed p19ARF expression to be highly heterogeneous – 
generally limited to specific regions of certain tumours. Stratification of lung tumours into 
low and high-grade, the latter comprising mostly adenocarcinomas (Supplemental Figure 4) 
20, revealed that p19ARF was confined mostly to high-grade tumours. High p19ARF cells 
were only rarely observed in low-grade tumours and, when present, were restricted to small, 
sporadic foci. Close examination of transitional tumours comprising clearly defined high 
and low-grade regions showed p19ARF to be highly expressed only in high-grade/carcinoma 
areas (Figure 2C).
Since p19ARF is a potent activator of p53, we next ascertained whether the high-grade 
regions expressing elevated p19ARF coincide with those that spontaneously activate p53 
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following restoration. p53 function was acutely restored in KR;p53KI/KI mice and tumours 
analyzed for expression of p19ARF and p21cip1. Upon p53 restoration, tumour areas positive 
for p19ARF overlapped extensively with those positive for p21cip1 (Figure 2D): ~70% of 
p19ARF–positive cells from Tam-treated mice stained positive for p21cip1 compared with 2% 
of control. That p19ARF plays a causal role in engaging p53-mediated tumour suppression in 
high-grade tumours was corroborated by the rapid cessation of cell proliferation specific to 
p19ARF-positive regions following p53 restoration (Figure 3A – Tam, two upper rows). By 
contrast, proliferation remained high in p19ARF-negative tumours after p53-restoration 
(Figure 3A –Tam, two lower rows). Of note, no γ-H2AX staining DNA damage foci were 
detected in KR;p53KI/KI lung tumours, although they were readily evident in tumours from 
γ-irradiated mice (Supplemental Figure 5). The remarkable overlap between p53 activation 
and p19ARF expression strongly implicates p19ARF, and not DNA damage, as the 
endogenous signal responsible for triggering p53 in high-grade lung tumours.
Although germ-line p53 deficiency significantly accelerates lung tumour progression and 
malignancy in KR mice 15, our data indicate that p53 tumour suppression acts only at later 
stages of tumour evolution. Since p53 is specifically activated in the most aggressive tumour 
cells, its restoration in a mixed tumour population should lead to a shift downwards in 
assigned tumour grade. Indeed, 7 days of p53 restoration in KR;p53KI/KI mice harbouring a 
mixture of low and high-grade tumours elicited a downward shift in the frequency of high-
grade tumours (from 29% to 11%) and a pro rata increase in the proportion of low-grade 
tumours (from 71% to 89%) (Figure 3B and Supplemental Figure 6). The percentage of 
BrdU-positive high-grade cells was also dramatically reduced following treatment (Figure 
3C).
Our data show that the p19ARF/p53 pathway is only engaged in high-grade KR;p53KI/KI 
cells, even though all tumour cells harbour oncogenic KrasG12D. Hence, oncogenic activity 
of Kras is not alone sufficient to induce p19ARF and engage p53-mediated tumour 
suppression. Interestingly, recent in vivo studies indicate that intrinsic tumour suppression is 
only engaged when oncogenic signals are preternaturally elevated 11,12. Such observations 
echo in vitro data showing that expression of oncogenic KrasG12D from its endogenous 
promoter induces proliferation and immortalization whereas KrasG12D over-expression 
engages p53-dependent replicative senescence 21,22. Since marked up-regulation of the 
MAPK-pathway is a characteristic feature of advanced lung tumours in both mice 15 and 
NSCLC in humans 23, we asked whether induction of p19ARF in high-grade tumours is a 
consequence of elevated flux through the Ras signalling network. Indeed, immunostaining 
showed a remarkably tight spatial concordance of tumour cells exhibiting elevated ERK 
phosphorylation (p-ERK), a signature of downstream Ras signalling, and those with high 
p19ARF (Figures 4A and Supplemental Figure 7) – the cell-by-cell overlap between up-
regulation of p19ARF and p-ERK was 91.2% (n=1312; STDEV: 3.77). Hence, increased flux 
through oncogenic KrasG12D is the likely mechanism for both malignant progression and 
concomitant activation of (and eventual counter-selection against) the p19ARF/p53 tumour 
suppressor pathway.
Many potential mechanisms might underlie the dramatic up-regulation of p-ERK we observe 
in high-grade lung tumours, including changes in Kras copy number (known to occur in 
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human NSCLC), secondary inactivation of the wt Kras allele, inactivation of Kras negative 
feedback mechanisms and incidental activation of cooperating oncogenes 24–27. Initial 
analysis of whole low versus high-grade tumours suggested downregulation of Sprouty 2 or 
loss of the wt Kras allele as possible mechanisms for Kras signal up-regulation in high p-
ERK tumours (Supplemental Figure 8). Since elevated Ras signalling is a property peculiar 
to high-grade tumour regions, we used p-ERK staining to demarcate high, low and mixed p-
ERK areas of individual tumours (Figure 4B, upper panel). These tumour regions were 
individually laser microdissected and their genomic DNA extracted and assessed for the 
relative copy representation of wt versus mutant Kras alleles. We saw variable levels of wt 
Kras retention in the low/mixed p-ERK tumour tissues, ranging from 100% in the low p-
ERK tumour 14 through to partial or total loss in the mixed grade tumours (e.g. 21 and 18). 
Remarkably, the wt Kras allele was lost in all high p-ERK tumours (Figure 4B, lower panel) 
and the mutant Kras allele often duplicated (Supplemental Figure 9). Overall, across all 
tumour samples Kras allelic imbalance, a known mechanism by which Ras signal strength is 
elevated 27, correlated tightly with high p-ERK.
Long-lived organisms must solve the problem of suppressing cancer without compromising 
the facility of normal cells to proliferate. This requires an accurate means of distinguishing 
between normal and oncogenic signals. However, emerging evidence hints at a “flaw” in 
how our tumour suppressor pathways have evolved – rather than responding to the aberrant 
signal persistence that is actually responsible for oncogenesis, mammalian intrinsic tumour 
suppressor pathways have instead evolved to respond to the unusual elevation in signal 
intensity that often (but not invariably) accompanies oncogenic activation 11. Paradoxically, 
therefore, low-level oncogenic activities may be more efficient at initiating tumourigenesis 
than high-level oncogenic signals because they “fall beneath the radar” of tumour 
surveillance 28: high-level oncogenic signals, which appear necessary to drive progression 
to malignancy, are tolerable only once p53 function has been quelled.
At first glance, our data showing limited therapeutic impact of restoring p53 in established 
lung tumours appear at odds with previous studies 7–9. However, such studies utilized 
advanced, relatively homogenous tumours driven by high levels of oncogenic signalling that 
had already engaged the ARF pathway – hence the dramatic impact of re-instating p53. By 
contrast, the spontaneously evolving lung tumours that afflict KR mice are initiated by 
sporadic oncogenic activation of endogenous Kras at a level insufficient to engage p53. Our 
data suggest that it is only relatively late in their evolution, at the point when sporadic 
elevation of Ras signalling precipitates tumours into aggressive, high-grade lesions, that the 
p53 pathway is triggered. Such considerations offer a compelling rationale for the long-
baffling observation that selection for p53 pathway inactivation arises relatively late in the 
evolution of many solid human tumours.
The inability of low-level oncogenic signalling to engage p53 also casts a cautionary shadow 
over the potential efficacy of p53 restoration in treating cancer. Established tumours are 
typically comprised of heterogeneous clades of neoplastic clones that encompass all phases 
of oncogenic evolution. Although p53 restoration might cull the most malignant cells, less 
aggressive tumour cells driven by low-level oncogenic signals would presumably survive to 
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evolve another day. At best, then, p53 restoration as a single therapy would be a means of 
temporary tumour containment rather than eradication.
METHODS SUMMARY
Tumour induction and treatment
Animals were maintained under UCSF IACUC-approved protocols. KR 5 and p53KI mice 14 
progeny were infected with Adenovirus-CRE (5 × 107 pfu/mouse) by nasal inhalation at 8 
weeks of age 5. p53 function was restored by intraperitoneal injection of Tamoxifen (1 mg/
mouse/daily) 7,10,14. Where appropriate, mice were irradiated (4 Gy) 2 hr after Ctrl/Tam 
treatment using a Mark 1–68 137Cesium source (0.637 Gy/min). A minimum of 5 mice per 
cohort was used for each experiment.
Immunohistochemistry and immunoflourescence
Primary antibodies used were p19ARF (gift from CJ. Sherr and MF Roussel 29); p21 (BD 
Pharmigen #556430); Ki67 (SP6 Neomarkers); P-ERK (Cell Signaling Technologies #4376) 
and phospho-histone H2AX (Upstate #05-636). They were detected with HRP-/Alexa-
conjugated secondary antibodies. An Apoptag™ kit (Chemicon) was used for TUNEL.
LCM, expression and copy number analysis
For CDKN1A Taqman analysis 8, LCM isolation of frozen samples 30 was followed by 
RNA preparation (Arcturus PicoPure RNA Isolation kit, Arcturus Engineering) and cDNA 
production (iScript cDNA Synthesis kit, Bio-Rad). For copy number analysis, LCM (Zeiss 
P.A.L.M) collection of paraffin samples was followed by DNA isolation (QIAamp® DNA 
Micro Kit #56304) and Taqman (probes: β-Actin: Mm00607939_s1; Kras: 
Mm03053281_s1, Applied Biosystems) or PCR (primers: KrasHind3_F 
GCCATTAGCTGCTACAAAACAGTA and KrasHind3_R 
CCTCTATCGTAGGGTCGTACTCAT). Following PCR the KrasG12D and Kraswt alleles 
were distinguished by the presence of a KrasG12D-specific HindIII site in the amplified 
fragment (WT = 400 bp; KrasG12D = 300 +100 bp).
MicroCT X-Ray Tomography
Pre- (day 0) and post-therapy (day 7) MicroCT data was acquired using a FLEX™ X-O™ 
system (Gamma Medica-Ideas, Northridge, CA). Only clearly discrete tumours were 
measured.
Immunoblot Analysis
Whole-cell lysates from dissected tumour halves were immunoblotted with anti-Spry 2 
(Abcam ab50317), Dusp6 (Santa Cruz sc-28902) or β-actin (Sigma A5441) antibodies.
METHODS
Mice, adenoviral infection and treatments
Animals were maintained in SPF conditions under UCSF IACUC-approved protocols. KP 5 
and p53KI mice 14 were crossed and KP and KP;p53KI/KI animals were infected by nasal 
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inhalation with Adenovirus-CRE (5 × 107 pfu/mouse) at 8 weeks of age, as described 5. p53 
function was restored by treating mice with Tamoxifen (1 mg/mouse/daily) delivered by 
intraperitonial injection, as described 7,10,14. Where appropriate, mice were irradiated (4 
Gy) 2 hr after Ctrl/Tam treatment using a Mark 1–68 137Cesium source (0.637 Gy/min). A 
minimum of 5 mice per cohort were used for each experiment.
Immnunohistochemistry and immunoflourescence
IHC stainings were performed on z-fix fixed, 5 µm paraffin embedded tissue sections. 
Sections were incubated overnight at 4°C with the following primary antibodies: p19ARF 
(gift from CJ. Sherr and MF Roussel 29); p21 (BD Pharmigen #556430, San Jose, CA) ; 
Ki67 (SP6, Neomarkers: Fremont, CA); P-ERK (Cell Signaling Technologies #4376, 
Danvers, MA), phospho-Histone H2AX (Upstate #05-636, Billerica, MA). Antibodies were 
detected using Vectastain ABC™ detection (Vector Laboratories, Burlingame, CA) or with 
specific biotinylated secondaries (anti-Rat biotinylated, Vector Laboratories BA-4001 and 
anti-Rabbit biotinylated, Dako #E0432) followed with stable diamobenzidine treatment 
(Invitrogen, Carlsbad, CA). Alternatively, Alexa-conjugated mouse, rat or rabbit IgG 
antibodies were used (Molecular Probes). TUNEL staining was performed using the 
Apoptag™ flourescein labeled kit (Chemicon) according to the manufacturers directions.
Laser capture microdissection, expression and copy number analysis
For RNA analysis 30 µm sections from fresh frozen lung tissue were fixed, stained and laser 
capture microdissected, as previously described 30. Total RNA was isolated and DNase I 
treated using the Arcturus PicoPure RNA Isolation kit (Arcturus Engineering, Mountain 
View, CA). cDNA was produced utilising iScript cDNA Synthesis kit (Bio-Rad, Hercules, 
CA). Real time quantitative PCR (Q-PCR) was performed as previously described 8. For 
copy number analysis 5 µm sections were briefly de-paraffinised and laser capture 
microdissected using a Zeiss P.A.L.M. LCM microscope. Genomic DNA was isolated using 
the QIAamp® DNA Micro Kit #56304 and analysed by Taqman or PCR. Copy number 
Taqman analysis was carried out using the following probes from Applied Biosystems: β-
Actin: Mm00607939_s1; Kras: Mm03053281_s1. PCR was performed using the following 
Kras-specific primers: KrasHind3_F GCCATTAGCTGCTACAAAACAGTA and 
KrasHind3_R CCTCTATCGTAGGGTCGTACTCAT. Due to the presence of a unique 
HindIII restriction site in the KrasG12D allele, the mutant and wt alleles can be distinguished 
based on their HindIII restriction-digestion profile (WT = 400 bp and KrasG12D = 300 +100 
bp).
Micro-computed X-ray tomography
Computed tomography (CT) was performed using a micro CT system (FLEX™ X-O™, 
Gamma Medica-Ideas, Northridge, CA) with an x-ray source with 75 kVp and 0.315 mA. 
CT data were acquired as 512 projections over 120 seconds of continuous x-ray exposure. 
Pre-therapy CT data were acquired as the baseline time point and post-therapy CT 
performed after 7 days of sustained Tamoxifen administration. Only clearly discrete tumours 
were picked for volume measurements. Volumes of interest were drawn on axial slices, and 
the total tumour volumes were calculated planimetrically.
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Whole-cell lysates from dissected tumour halves were prepared and immunoblotted with 
anti-Spry 2 (Abcam ab50317, Cambridge, MA), Dusp6 (Santa Cruz sc-28902) or β-actin 
(Sigma A5441, St. Louis, MO) antibodies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Heterogeneous therapeutic impact of p53 restoration in KrasG12D driven lung tumours
a. Schematic representation of the experimental treatment regime. KrasG12D was activated in 
the lung epithelium of 8 week old KR;p53KI/KI mice by adenoviral-Cre nasal inhalation and 
the resulting tumours treated with Tam or vehicle (Ctrl) 15 weeks after adenoviral infection.
b. Haematoxylin and Eosin staining of lung sections from KR;p53KI/KI mice showing 
tumour load after 7 daily control (Ctrl) or Tam treatments.
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c. Quantification of Ki67 positive cells per lung tumour from 7 day Tam/Ctrl-treated 
KR;p53KI/KI mice. Error bars indicate standard error of mean (Ctrl: s.e.m=1.20 n=55; Tam: 
s.e.m=1.31 n=37). * P=0.0003, Student’s t-test.
d. Percent of apoptotic (TUNEL-positive) tumours (scored as a minimum of 1 positive cell 
per tumour section) in 7 day Ctrl and Tam treated KR;p53KI/KI lungs (n=37 Ctrl; n=22 Tam 
treated tumours). * P=0.0064, Pearson Chi square.
e. KR;p53KI/KI lung tumours from KR;p53KI/KI treated for 6 hrs with Tam, showing either no 
discernible TUNEL staining (Neg) or significant levels of TUNEL staining (Pos). Scale 
bar=100 µm.
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Figure 2. Heterogeneous p53 activation and p19ARF up-regulation in KR;p53KI/KI tumours
a. MicroCT-derived plots depicting changes in tumour volume during a 7-day treatment. 10 
independent tumours are shown before (day 0) and after (day 7) daily Tam (red lines, filled 
symbols) or sham (black lines, open symbols) treatments.
b. Taqman analysis of CDKN1A expression in individual laser-captured lung tumours from 
KR;p53KI/KI mice treated for 7 days with vehicle (black circles) or Tam (red squares). 
Tumours were harvested 24 hrs after the final Ctrl/Tam treatment. Where indicated (IR +, 
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left panel) mice were exposed to a single dose of γ-radiation 2 hrs after the last Tam/Ctrl 
treatment. Each circle/square represents a single tumour.
c. IHC data comparing levels of p19ARF expression in low and high-grade tumours as well 
as in transitional lesions exhibiting both low and high-grade features. Scale bars=50 µm.
d. Co-immunostaining for p19ARF and p21cip1 in KR;p53KI/KI lung tumours from mice 
treated for 6 hrs with Tam. Representative fields shown, one at low (upper panel) and one at 
high magnification (lower panel). Scale bar=50 µm.
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Figure 3. p53 restoration targets high-grade, but not low-grade, lung tumour cells
a. Co-immunostaining for p19ARF and the proliferation marker Ki67 in lung tumours from 
KR;p53KI/KI mice treated for 24 hrs with vehicle (Ctrl, upper row) or Tam (four lower rows). 
Row 2 and 3 illustrate the profound anti-proliferative impact (low Ki67) of p53 restoration 
in tumours with high p19ARF levels. By contrast, the lower two rows show lack of growth 
inhibition following p53 restoration in tumours lacking detectable p19ARF. Scale bar = 50 
µm.
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b. Quantification of low versus high-grade tumour frequencies in lungs of KR;p53KI/KI mice 
treated for 7 days with either vehicle (Ctrl) or Tam (n=143 Ctrl; n=163 Tam). P=0.0001, 
Pearson Chi square.
c. Representative images show IHC for BrdU in high-grade tumours from 7-day treated Ctrl 
(Ctrl, upper panel) or Tam mice (lower panel). BrdU was administered 2 hrs before 
harvesting. Arrows highlight high-grade cells in each tumour (filled, BrdU positive and 
open, BrdU negative). Scale bars=50 µm.
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Figure 4. High-grade lung tumours exhibit increased Kras signalling
a. IHC for p19ARF and p-ERK in consecutive sections of three independent low-to-high-
grade transition tumours from KR;p53KI/KI mice. Scale bar = 200 µm.
b. Kras allele analysis was performed on genomic DNA from KR;p53KI/KI lung tumours 
following laser capture microdissection. p-ERK IHC was used to define areas of low, mixed 
or high p-ERK (upper panel, Scale bar=50µm) and consecutive slides used for LCM of 
defined regions (see dotted areas). DNA was isolated from LCM material and the Kras 
genomic region amplified by PCR and digested with HindIII (lower panel). For each 
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tumour, the undigested (−) and digested (+) PCR fragments were run alongside and the wt 
(Kras, higher band) and mutant alleles (G12D, lower band) are indicated. Control lung 
tissue from heterozygous (KrasG12D/+: Ctrl) and wild-type (WT) mice was also analyzed.
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